Subscribe to RSS

DOI: 10.1055/s-0045-1809176
Preoperative Radiotherapy (Preop-RT) Improves Pathological Complete Response Rates in Partial Responders (PR) to Primary Systemic Chemotherapy (PST) in Locally Advanced Breast Cancers (LABC)
Authors
Abstract
Introduction
Preoperative radiotherapy (preop-RT) can be used as one strategy to improve pathological complete response rates in locally advanced breast cancer. Hence, we conducted a pilot study of preop-RT in partial responders to primary systemic chemotherapy (PST).
Methods
Standard PST comprising of four cycles of Adriamycin/cyclophosphamide followed by four cycles of taxanes (along with trastuzumab in Her2-neu enriched) was initiated. After two cycles of taxanes, partial responders (PRs) were enrolled onto preop-RT (40 Gy/15#/3 weeks to whole breast followed by boost dose of 10 Gy/4#/1 week to gross tumor with 5 mm margin [clinical target volume] and 10 mm margin [planning target volume] by three-dimensional conformal radiation therapy. Field-in-field technique was used whenever the need to correct dose heterogeneity arose. The remaining two cycles of taxanes were completed 3 weeks after the completion of RT. Surgical intervention was initiated 6 weeks after the completion of PST. The intention of such a strategy was to keep an interval of 12 weeks between completion of RT and surgery to achieve maximum downstaging. The primary endpoint was pathological complete response rate (ypCR).
Results
Twenty-one women were enrolled (median age 47 years, 35% premenopausal, 50% upper outer quadrant, 65% T4, 85% node positive, 40% luminal A, 10% luminal B, 15% Her-2-neu enriched, and 35% triple-negative breast cancer [TNBC]). Twenty-eight percent underwent breast conservation and the rest modified radical mastectomy (n = 13) and 2 did not undergo surgery (elderly [n = 1], lost to follow-up [n = 1]). ypCR(T) rate was 53% and ypCR(N) was 59%. ypCR(T) rate was 50% in Her-2 positive and 25% in TNBC, and 33.3% in luminal A. At a median follow-up of 24 months, the median overall survival is 41 months and 2 (both TNBC, ypCR, and ypPR) developed distant metastasis (in lung and soft tissue).
Conclusion
This pilot study reveals encouraging results in high-risk subsets and this potential of preop-RT should be explored further in larger studies.
Keywords
locally advanced breast cancer - neoadjuvant chemotherapy - preoperative radiotherapy - pathological complete responseEthical Approval
This work has been approved by the institute's Ethics Committee.
Authors' Contributions
S.A. was involved in the study design, data collection and analysis, as well as manuscript writing. A.G. contributed to data analysis. G.C. facilitated patient recruitment, performed the surgeries, and analyzed postoperative complications.
This work has been presented in UP AROI, Breilly, 2022, and won the best paper award.
Publication History
Received: 24 May 2023
Accepted: 18 April 2025
Article published online:
15 May 2025
© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007; 31 (05) 1031-1040
- 2 Gupta D, Raina V, Rath GK, Shukla NK, Mohanti BK, Sharma DN. Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: eight-year experience from single centre. Indian J Cancer 2011; 48 (04) 410-414
- 3 Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK, Sharma DN. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev 2014; 15 (05) 1989-1992
- 4 Cortazar P, Zhang L, Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164-172
- 5 Sivasanker M, Sistla SC, Manwar SA, Vivekanandam S. Clinical and pathologic response following taxane based neoadjuvant chemotherapy in locally advanced breast cancer patients in a tertiary care centre in India. Indian J Cancer 2016; 53 (02) 220-225
- 6 Chauhan A, Sharma MM, Kumar K. Evaluation of surgical outcomes of oncoplasty breast surgery in locally advanced breast cancer and comparison with conventional breast conservation surgery. Indian J Surg Oncol 2016; 7 (04) 413-419
- 7 Rastogi P, Anderson SJ, Bear HD. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26 (05) 778-785
- 8 Agarwal G, Sonthineni C, Mayilvaganan S, Mishra A, Lal P, Agrawal V. Surgical outcomes of primary versus post-neoadjuvant chemotherapy breast conservation surgery: a comparative study from a developing country. World J Surg 2018; 42 (05) 1364-1374
- 9 Lightowlers SV, Boersma LJ, Fourquet A. et al. Preoperative breast radiation therapy: indications and perspectives. Eur J Cancer 2017; 82: 184-192
- 10 Bollet MA, Belin L, Reyal F. et al. Preoperative radio-chemotherapy in early breast cancer patients: long-term. Radiother Oncol 2011; 8: 17
- 11 Loibl S, Volz C, Mau C. et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 2014; 144 (01) 153-162
- 12 Coelho RC, Da Silva FML, Do Carmo IML, Bonaccorsi BV, Hahn SM, Faroni LD. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy?. Breast 2017; 31: 192-196
- 13 Palta M, Yoo S, Adamson JD, Prosnitz LR, Horton JK. Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2012; 82 (01) 37-42
- 14 Peterson D, Truong PT, Parpia S. et al; RAPID trial investigators. Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. Int J Radiat Oncol Biol Phys 2015; 91 (05) 968-976
- 15 Semiglazov VF, Topuzov EE, Bavli JL. et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5 (07) 591-595
- 16 de Wild SR, de Munck L, Simons JM. et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol 2022; 23 (09) 1201-1210
- 17 Shanta V, Swaminathan R, Rama R, Radhika R. Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990-1999. Int J Radiat Oncol Biol Phys 2008; 70 (01) 51-58
- 18 Riet FG, Fayard F, Arriagada R. et al. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up. Eur J Cancer 2017; 76: 45-51
- 19 Bondiau P-Y, Courdi A, Bahadoran P. et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys 2013; 85 (05) 1193-1199
- 20 Horton JK, Blitzblau RC, Yoo S. et al. Preoperative single-fraction partial breast radiation therapy: a novel phase 1, dose-escalation protocol with radiation response biomarkers. Int J Radiat Oncol Biol Phys 2015; 92 (04) 846-855
- 21 Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 2004; 59 (04) 1062-1073
- 22 Paillocher N, Florczak AS, Richard M. et al. Evaluation of mastectomy with immediate autologous latissimus dorsi breast reconstruction following neoadjuvant chemotherapy and radiation therapy: a single institution study of 111 cases of invasive breast carcinoma. Eur J Surg Oncol 2016; 42 (07) 949-955
- 23 Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C. et al. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. Radiat Oncol 2009; 4: 24
- 24 Corradini S, Niyazi M, Niemoeller OM. et al. Adjuvant radiotherapy after breast conserving surgery - a comparative effectiveness research study. Radiother Oncol 2015; 114 (01) 28-34
- 25 Vasmel JE, Charaghvandi RK, Houweling AC. et al. Tumor response after neoadjuvant magnetic resonance guided single ablative dose partial breast irradiation. Int J Radiat Oncol Biol Phys 2020; 106 (04) 821-829
- 26 Loibl S, Gianni L. HER2-positive breast cancer. Lancet 2017; 389 (10087): 2415-2429
- 27 Mukai H, Watanabe T, Mitsumori M. et al; Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Jpn Clin Oncol Group Study JCOG0306. Oncology 85 (06) 336-41
- 28 Calitchi E, Kirova YM, Otmezguine Y, Feuilhade F, Piedbois Y, Le Bourgeois JP. Long-term results of neoadjuvant radiation therapy for breast cancer. Int J Cancer 2001; 96 (04) 253-259
- 29 Roth SL, Audretsch W, Bojar H, Lang I, Willers R, Budach W. Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol 2010; 186 (06) 299-306
- 30 Nichols EM, Dhople AA, Mohiuddin MM, Flannery TW, Yu CX, Regine WF. Comparative analysis of the post-lumpectomy target volume versus the use of pre-lumpectomy tumor volume for early-stage breast cancer: implications for the future. Int J Radiat Oncol Biol Phys 2010; 77 (01) 197-202
- 31 Batenburg MCT, Mink van der Molen DR, van der Leij F. et al; UMBRELLA study team. Patient-reported symptoms of late toxicity in patients with breast cancer treated with hypofractionated radiation therapy and the association with quality of life. Int J Radiat Oncol Biol Phys 2023; 115 (05) 1181-1191
- 32 Poleszczuk J, Luddy K, Chen L. et al. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 2017; 19 (01) 75
- 33 Thiruchelvam PTR, Leff DR, Godden AR. et al; PRADA Trial Management Group. Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study. Lancet Oncol 2022; 23 (05) 682-690
- 34 Nichols E, Kesmodel SB, Bellavance E. et al. Preoperative accelerated partial breast irradiation for early-stage breast cancer: preliminary results of a prospective, phase 2 trial. Int J Radiat Oncol Biol Phys 2017; 97 (04) 747-753
- 35 Guidolin K, Yaremko B, Lynn K. et al. Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy. Curr Oncol 2019; 26 (03) e334-e340
